X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used to support the development of curative therapies by using Prime Editing to correct CFTR mutations at the natural genetic locus, for the treatment of Cystic Fibrosis (CF).
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Prime Medicine
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Funding January 25, 2024
Details:
The funding will advance ARCT-032, a novel messenger RNA (mRNA) therapeutic candidate formulated with Arcturus’ LUNAR® delivery technology for the treatment of Cystic Fibrosis.
Lead Product(s): ARCT-032
Therapeutic Area: Genetic Disease Product Name: ARCT-032
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Arcturus Therapeutics
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 26, 2023
Details:
If the therapy is successful, people with CF would be able to decrease the number of enzyme pills they must take to digest food properly from a handful of pills to only one per meal.
Lead Product(s): Enzyme-based Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Anagram Therapeutics
Deal Size: $15.5 million Upfront Cash: Undisclosed
Deal Type: Funding April 04, 2023
Details:
AR-501 is a novel, small molecule and an inhalable form of gallium citrate, which acts as an iron analog to starve bacteria of iron. Gallium is believed to inhibit multiple iron-dependent synthetic and metabolic pathways required for pathogenicity.
Lead Product(s): Gallium Citrate
Therapeutic Area: Genetic Disease Product Name: AR-501
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Aridis Pharmaceuticals
Deal Size: $12.5 million Upfront Cash: Undisclosed
Deal Type: Funding December 12, 2022
Details:
BiomX has been given grant to support a clinical trial of BX004, a phage therapy to fight Pseudomonas aeruginosa infections in people with cystic fibrosis (CF). In lab experiments conducted by BiomX, BX004 killed antibiotic-resistant strains of P. aeruginosa.
Lead Product(s): BX004
Therapeutic Area: Infections and Infectious Diseases Product Name: BX004
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: BiomX
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Funding January 05, 2022
Details:
The award provided by the Cystic Fibrosis Foundation will generate both in vitro and in vivo data about PLG0301 and PLG0206, which may potentially support an Investigational New Drug (IND) application with the FDA for its continued development.
Lead Product(s): PLG0301
Therapeutic Area: Infections and Infectious Diseases Product Name: PLG0301
Highest Development Status: PreclinicalProduct Type: Peptide
Recipient: Peptilogics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding January 05, 2022
Details:
The CF Foundation’s funding will support Phase 2 study of opelconazole. The objective of the study is to assess the safety and tolerability and patient’s ability to complete the course of treatment when used to prevent invasive pulmonary fungal infections in lung transplant.
Lead Product(s): Opelconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: PC945
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Pulmocide
Deal Size: $3.5 million Upfront Cash: Undisclosed
Deal Type: Funding December 06, 2021
Details:
Pioneering Medicines and the Cystic Fibrosis Foundation will partner with multiple companies within the Flagship ecosystem, leveraging emerging technologies including Tessera Therapeutics’ Gene WritingTM technology, targeted delivery modalities, and RNA technologies.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: Flagship Pioneering
Deal Size: $110.0 million Upfront Cash: Undisclosed
Deal Type: Partnership November 03, 2021
Details:
This new funding of up to $1.8 million will directly support IND-enabling toxicology studies of pravibismane and is in addition to $5.6 million previously awarded by the Foundation, for a combined total of up to $7.4 million.
Lead Product(s): Pravibismane
Therapeutic Area: Infections and Infectious Diseases Product Name: MBN-101
Highest Development Status: IND EnablingProduct Type: Small molecule
Recipient: Microbion
Deal Size: $7.4 million Upfront Cash: Undisclosed
Deal Type: Funding February 22, 2021
Details:
The funding will support a clinical trial to determine whether high doses of inhaled nitric oxide are safe and effective when used in conjunction with current standard-of-care therapies, including amikacin and azithromycin.
Lead Product(s): Nitric Oxide,Amikacin,Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Recipient: Beyond Air
Deal Size: $2.1 million Upfront Cash: Undisclosed
Deal Type: Funding February 16, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
